देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
INSULIN GLARGINE
ELI LILLY CANADA INC
A10AE04
INSULIN GLARGINE
100UNIT
SOLUTION
INSULIN GLARGINE 100UNIT
SUBCUTANEOUS
100
Schedule D
INSULINS
Active ingredient group (AIG) number: 0147062001; AHFS:
CANCELLED POST MARKET
2019-08-22
_ BASAGLAR™ Product Monograph _ _Page 1 of 52_ PRODUCT MONOGRAPH BASAGLAR™ insulin glargine (rDNA origin) Solution for Injection, 100 units/mL THERAPEUTIC CLASSIFICATION Anti-diabetic Agent ATC code: A10AE04 Long-acting Recombinant Human Insulin Analogue ©ELI LILLY CANADA INC. 3650 Danforth Avenue Scarborough, Ontario M1N 2E8 Submission Control No: 200289 Date of Approval: February 17, 2017 _ BASAGLAR™ Product Monograph _ _Page 2 of 52_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION.............................................................. 3 SUMMARY PRODUCT INFORMATION .......................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................... 3 CONTRAINDICATIONS ..................................................................................................... 4 WARNINGS AND PRECAUTIONS ................................................................................... 5 ADVERSE REACTIONS ................................................................................................... 11 DRUG INTERACTIONS .................................................................................................... 22 DOSAGE AND ADMINISTRATION................................................................................ 23 OVERDOSAGE .................................................................................................................. 26 ACTION AND CLINICAL PHARMACOLOGY .............................................................. 27 STORAGE AND STABILITY ........................................................................................... 30 SPECIAL HANDLING INSTRUCTIONS ......................................................................... 31 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................... 31 PART II: SCIENTIFIC INFORMATION ................................................................................... 33 PHARMACEUTICAL पूरा दस्तावेज़ पढ़ें